These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29617362)

  • 1. A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression.
    Stefanski HE; Jonart L; Goren E; Mulé JJ; Blazar BR
    PLoS One; 2018; 13(4):e0193461. PubMed ID: 29617362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 3. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
    Yang SC; Hillinger S; Riedl K; Zhang L; Zhu L; Huang M; Atianzar K; Kuo BY; Gardner B; Batra RK; Strieter RM; Dubinett SM; Sharma S
    Clin Cancer Res; 2004 Apr; 10(8):2891-901. PubMed ID: 15102698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector.
    Terando A; Roessler B; Mulé JJ
    Cancer Gene Ther; 2004 Mar; 11(3):165-73. PubMed ID: 14726959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCL21-induced immune cell infiltration.
    Ashour AE; Turnquist HR; Singh RK; Talmadge JE; Solheim JC
    Int Immunopharmacol; 2007 Feb; 7(2):272-6. PubMed ID: 17178395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of targeted cell migration by cutaneous administration of a DNA vector encoding a biologically active chemokine CCL21.
    Jalili A; Pashenkov M; Kriehuber E; Wagner C; Nakano H; Stingl G; Wagner SN
    J Invest Dermatol; 2010 Jun; 130(6):1611-23. PubMed ID: 20182442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction.
    Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
    Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.
    Baratelli F; Takedatsu H; Hazra S; Peebles K; Luo J; Kurimoto PS; Zeng G; Batra RK; Sharma S; Dubinett SM; Lee JM
    J Transl Med; 2008 Jul; 6():38. PubMed ID: 18644162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.
    Zhang SN; Choi IK; Huang JH; Yoo JY; Choi KJ; Yun CO
    Mol Ther; 2011 Aug; 19(8):1558-68. PubMed ID: 21468000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrogation of CCL21 chemokine function by transgenic over-expression impairs T cell immunity to local infections.
    Unsoeld H; Mueller K; Schleicher U; Bogdan C; Zwirner J; Voehringer D; Pircher H
    Int Immunol; 2007 Nov; 19(11):1281-9. PubMed ID: 17914120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of CCL19 by DC-Lamp+ mature dendritic cells in human lymph node versus chronically inflamed skin.
    Katou F; Ohtani H; Nakayama T; Nagura H; Yoshie O; Motegi K
    J Pathol; 2003 Jan; 199(1):98-106. PubMed ID: 12474232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCL21 is sufficient to mediate DC migration, maturation and function in the absence of CCL19.
    Britschgi MR; Favre S; Luther SA
    Eur J Immunol; 2010 May; 40(5):1266-71. PubMed ID: 20201039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAMP1/YitFc mice develop ileitis via loss of CCL21 and defects in dendritic cell migration.
    Mikulski Z; Johnson R; Shaked I; Kim G; Nowyhed H; Goodman W; Chodaczek G; Pizarro TT; Cominelli F; Ley K
    Gastroenterology; 2015 Apr; 148(4):783-793.e5. PubMed ID: 25620669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
    Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Dörken B; Pezzutto A; Westermann J
    Cancer Gene Ther; 2012 Jan; 19(1):69-76. PubMed ID: 21997231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralymphatic CCL21 Promotes Tissue Egress of Dendritic Cells through Afferent Lymphatic Vessels.
    Russo E; Teijeira A; Vaahtomeri K; Willrodt AH; Bloch JS; Nitschké M; Santambrogio L; Kerjaschki D; Sixt M; Halin C
    Cell Rep; 2016 Feb; 14(7):1723-1734. PubMed ID: 26876174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR5-transduced bone marrow-derived dendritic cells traffic to B cell zones of lymph nodes and modify antigen-specific immune responses.
    Wu MT; Hwang ST
    J Immunol; 2002 May; 168(10):5096-102. PubMed ID: 11994462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes.
    Sugaya M; Fang L; Cardones AR; Kakinuma T; Jaber SH; Blauvelt A; Hwang ST
    J Immunol; 2006 Dec; 177(11):7665-72. PubMed ID: 17114436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
    Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
    Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell-based vaccines for pancreatic cancer and melanoma.
    Mulé JJ
    Ann N Y Acad Sci; 2009 Sep; 1174():33-40. PubMed ID: 19769734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.